Caris Life Sciences, Inc.

As of June 30, 2026, Caris Life Sciences, Inc. carries a market capitalization of 91.04B, placing it among publicly traded companies globally. Its enterprise value stands at 85.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Caris Life Sciences, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Caris Life Sciences, Inc. has 282.58M shares outstanding.

As of June 30, 2026, Caris Life Sciences, Inc. trades at a trailing price-to-earnings ratio of 49.54. The price-to-sales ratio is 5.26, and the price-to-book ratio stands at 8.81.

As of June 30, 2026, Caris Life Sciences, Inc. trades at an EV/EBITDA multiple of 27.98 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.77 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 85.08B versus a market cap of 91.04B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Caris Life Sciences, Inc. maintains a current ratio of 5.53, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.45, indicating elevated leverage, while an interest coverage ratio of 3.71 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. posted a return on equity (ROE) of 20.13, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 9.62, measuring how efficiently the asset base is converted into earnings. The company generates approximately 9.37M in revenue per employee across its workforce of 1,846.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.65 indicates how many times Caris Life Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. recorded an income tax benefit of -1.94M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 1.83B, leaving 1.84B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. generated 17.29B in revenue and converted that into 1.84B in net income, yielding earnings per share of 6.34. EBITDA reached 3.04B, while operating income came in at 2.68B.

As of June 30, 2026, Caris Life Sciences, Inc. holds 13.86B in cash and equivalents against 7.90B in total debt, resulting in a net debt position of -5.20B. Total book value stands at 10.34B, with working capital of 15.14B providing operational flexibility.

Caris Life Sciences, Inc. produced 2.94B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -393.58M in capital expenditures, free cash flow totaled 2.55B - equivalent to 9.03 per share.

Over the twelve months ended June 30, 2026, Caris Life Sciences, Inc. posted a gross margin of 69.66, reflecting its pricing power and cost economics. The operating margin of 15.49 and net profit margin of 10.62 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.73, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Caris Life Sciences, Inc. shareholders.

As of June 30, 2026, Caris Life Sciences, Inc. has an Altman Z-Score of 4.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.